نتائج البحث - Jeremy Force

  • يعرض 1 - 12 نتائج من 12
تنقيح النتائج
  1. 1
    Mechanisms of Therapeutic Antitumor Monoclonal Antibodies

    Mechanisms of Therapeutic Antitumor Monoclonal Antibodies حسب Li-Chung Tsao, Jeremy Force, Zachary C. Hartman

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Clinical trials of self-replicating RNA-based cancer vaccines

    Clinical trials of self-replicating RNA-based cancer vaccines حسب Michael A. Morse, Erika J. Crosby, Jeremy Force, Takuya Osada, Amy Hobeika, Zachary C. Hartman, Peter Berglund, Jonathan Smith, H. Kim Lyerly

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity

    Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications... حسب Paul Beaudry, Jeremy Force, George N. Naumov, Andrew Wang, Cheryl H. Baker, Anderson J. Ryan, Shay Söker, Bruce E. Johnson, Judah Folkman, John V. Heymach

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database

    Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database حسب Cecilia T. Ong, Brittany M. Campbell, Samantha M. Thomas, Rachel A. Greenup, Jennifer K. Plichta, Laura H. Rosenberger, Jeremy Force, Allison Hall, Terry Hyslop, E. Shelley Hwang, Oluwadamilola M. Fayanju

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT)

    The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT) حسب Oluwadamilola M. Fayanju, Yi Ren, Samantha M. Thomas, Rachel A. Greenup, Jennifer K. Plichta, Laura H. Rosenberger, Nina Tamirisa, Jeremy Force, Judy C. Boughey, Terry Hyslop, E. Shelley Hwang

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence

    RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence حسب Chao‐Chieh Lin, Nathaniel W. Mabe, Yi-Tzu Lin, Wen‐Hsuan Yang, Xiaohu Tang, Lisa Hong, Tianai Sun, Jeremy Force, Jeffrey R. Marks, Tso‐Pang Yao, James V. Alvarez, Jen‐Tsan Chi

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses

    APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses حسب Ashley V. DiMarco, Xiaodi Qin, Brock J. McKinney, Nina Marie G. Garcia, Sarah C. Van Alsten, Elizabeth A. Mendes, Jeremy Force, Brent A. Hanks, Melissa A. Troester, Kouros Owzar, Jichun Xie, James V. Alvarez

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib

    Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib حسب Ronan J. Kelly, Arun Rajan, Jeremy Force, Ariel López-Chávez, Corrine Keen, Liang Cao, Yunkai Yu, Peter L. Choyke, Barış Türkbey, Mark Raffeld, Liqiang Xi, Seth M. Steinberg, James R. Wright, Shivaani Kummar, Martin Gutierrez, Giuseppe Giaccone

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

    Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin حسب Geoffrey D. Girnun, Liang Chen, Jessica M. Silvaggi, Ronny Drapkin, Lucian R. Chirieac, Robert F. Padera, Rabi Upadhyay, Scott B. Vafai, Ralph Weissleder, Umar Mahmood, Elnaz Naseri, Stephanie Buckley, Danan Li, Jeremy Force, Kate McNamara, George D. Demetri, Bruce M. Spiegelman, Kwok‐Kin Wong

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

    A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013 حسب Foluso O. Ademuyiwa, Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, Elizabeth Claire Dees, Cesar A. Santa‐Maria, Roisín M. Connolly, Jeremy Force, Alvaro Moreno‐Aspitia, John M. Herndon, Madelyn Carmody, Sherri R. Davies, Sarah Larson, Kathleen L. Pfaff, Stephanie Jones, Jason L. Weirather, Anita Giobbie‐Hurder, Scott J. Rodig, Zheng Liu, Ian S. Hagemann, Elad Sharon, William E. Gillanders

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer

    Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer حسب Erika J. Crosby, Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiaoyi Yang, Tao Wang, Cong-Xiao Liu, Kay‐Uwe Wagner, William J. Muller, Lewis A. Chodosh, Gloria Broadwater, Terry Hyslop, Jonathan H. Shepherd, Daniel P. Hollern, Xiaping He, Charles M. Perou, Shengjie Chai, Benjamin K. Ashby, Benjamin G. Vincent, Joshua C. Snyder, Jeremy Force, Michael A. Morse, H. Kim Lyerly, Zachary C. Hartman

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

    Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 حسب Heather A. Parsons, Timothy Blewett, Xun Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana G. Abramson, Ayan R. Patel, Justin Cheng, Adam Brufsky, Justin Rhoades, Jeremy Force, Rong Liu, Tiffany A. Traina, Lisa A. Carey, Mothaffar F. Rimawi, Kathy D. Miller, Vered Stearns, Jennifer M. Specht, Carla I. Falkson, Harold J. Burstein, Antonio C. Wolff, Eric P. Winer, Nabihah Tayob, Ian E. Krop, G. Mike Makrigiorgos, Todd R. Golub, Erica L. Mayer, Viktor A. Adalsteinsson

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: